Chime Biologics, Leads Biolabs and BeiGene have entered a strategic partnership to expedite the development of a monoclonal antibody (mAb), LBL-007.
The three-way collaboration will also fast-track the production of the antibody for swift progression into clinics.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Developed by Leads Biolabs, LBL-007 acts on the lymphocyte-activating gene-3 (LAG-3) pathway.
Findings from the Phase I clinical trial in individuals with later-stage solid tumours demonstrate that the mAb enhances anti-tumour activity and has a favourable safety profile.
BeiGene and Leads had previously entered an authorisation and partnership deal under which Beigene received an international development and production licence for LBL-007, along with a licence for commercial production outside China.
Chime will support the manufacturing of the antibody and the materials required for the trials in mainland China.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company will also offer support for clinical development, as well as trial material production.
BeiGene global research and development director Dr Wang Lai stated: “The clinical candidate drug developed by Leads Biolabs has a broad prospect, not only enriching our tumour immunotherapy drug pipeline but also supporting us for global clinical development strategic priorities and development opportunities.
“Chime Biologics has advanced drug commercial manufacturing experience, a sound quality system and efficient production management, providing assurance of LBL-007 for global development.”
In May 2023, BeiGene also received approval from the Chinese National Medical Products Administration for Brukinsa (zanubrutinib) in four indications.
